Biotech Trust Up 150% in 3 Years

Over the last three years the Biotechnology index has returned an average of 45% every year. If you have a diversified portfolio and are looking for specialist exposure, consider this trust

Szymon Idzikowski 10 October, 2014 | 12:17PM

We think Biotech Growth Trust (BIOG) is a strong choice for investors looking for a dedicated sector fund.

Firstly, it has a strong management team whose depth of knowledge and experience in this sector is one of the best, in our view. Manager Richard D. Klemm brings industry as well as investment experience, having completed extensive studies in molecular biology, molecular and cell biology and economics. He graduated in 2000 and joined OrbiMed as a biotechnology analyst the same year. Comanager Geoffrey C. Hsu joined OrbiMed in 2002, having previously worked as an analyst in the health-care investment banking group at Lehman Brothers.

The duo can further leverage a well-resourced team of more than 50 investment analysts. The team brings a mix of background from both investment and industry; in addition, the group’s private equity and venture capital investment arm also adds insight that benefits the investment process.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Biotech Growth Ord824.00 GBX0.12

About Author

Szymon Idzikowski

Szymon Idzikowski  is a closed-end fund analyst with Morningstar.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites